RE: Today15 Jun 2026 11:01
From the chairman's statement in the year end report. for clarity.
"... £2.5 million after the year end. This financing in itself would take us through and beyond the next phase of our Phase 1 trials, which involves the treatment of a further three patients with an escalated dose. In addition, we have just announced the raise of a further equity raise of £3 million, which we believe will be sufficient to allow us to take the full Phase 1 trials to completion."